De Novo device
dermaPACE System
Sanuwave, Inc. · Extracorporeal Shock Wave Device For Treatment Of Diabetic Foot Ulcers (PZL, Class II) · First FDA decision Dec 28, 2017, newest Dec 28, 2017Chronic wounds and ulcersDiabetes
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
De Novo pathway
Device trials
4
Naming "dermaPACE"
MAUDE reports
0
Brand "dermaPACE", since 2015
PubMed studies
2
Mentioning "dermaPACE"
AI summary across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- dermaPACE SystemNew device typeDe Novo
DEN160037 · Decided Dec 28, 2017 · 521 days after receipt
Device type: Extracorporeal Shock Wave Device For Treatment Of Diabetic Foot Ulcers (PZL) · General & Plastic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Services Provided for the Diagnosis and Treatment of Diabetic Sensory Neuropathy with Loss of Protective Sensation (aka Diabetic Peripheral Neuropathy)National determinationOn the books70.2.1Updated Aug 17, 2023
- Treatment of Decubitus UlcersNational determinationOn the books270.4Updated Apr 20, 2020
- Extracorporeal Shock Wave Therapy (ESWT)Local determinationIn effectL38775Palmetto GBAUpdated Sep 6, 2024
Clinical trials
Device studies on ClinicalTrials.gov that name "dermaPACE", any status and sponsor, newest update first.
SANUWAVE, Inc.Not on our public-company list
NCT03640988 · 2 participants · Start Apr 25, 2019 · Primary completion Jan 3, 2021
Device: dermaPACE · For: Diabetic Foot Ulcer
Sites: Newark, New Jersey
Hospital Universitari Vall d'Hebron Research InstituteAcademic, hospital or other
NCT04558944 · 40 participants · Start Jan 1, 2017 · Primary completion Feb 15, 2019
Device: Extracorporal Shock Wave Therapy · For: Cicatrix, Hypertrophic
Sites: Barcelona, Spain
- Effectiveness of dermaPACE™ Device and Standard Treatment Compared to Standard Treatment Alone for Diabetic Foot UlcersPivotal-lookingCompleted
SANUWAVE, Inc.Not on our public-company list
NCT00536744 · 206 participants · Start Oct 2007 · Primary completion Jun 2010
Device: acoustical pulse energy (extracorporeal shockwave) · For: Diabetic Foot Ulcers
Sites: Phoenix, Arizona; Tucson, Arizona; Castro Valley, California · 23 sites in all
SANUWAVE, Inc.Not on our public-company list
NCT01824407 · 90 participants (planned) · Start Mar 2013 · Primary completion Apr 2014
Device: Electrohydraulic-generated shock wave; Sham device plus standard of care · For: Diabetic Foot Ulcers
Sites: Phoenix, Arizona; Tucson, Arizona; Long Beach, California · 19 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "dermaPACE", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code PZL
2 reports: 0 malfunction, 2 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "dermaPACE"[tiab]. The summary above synthesizes these.
- Diabetic foot ulcer treatment with focused shockwave therapy: two multicentre, prospective, controlled, double-blinded, randomised phase III clinical trials.
Snyder R, Galiano R, Mayer P, et al. · J Wound Care · 2018Clinical Trial, Phase III, Multicenter Study
- Focused shockwave therapy in diabetic foot ulcers: secondary endpoints of two multicentre randomised controlled trials.
Galiano R, Snyder R, Mayer P, et al. · J Wound Care · 2019Clinical Trial, Phase III, Multicenter Study
Other devices of this type
Also filed under product code PZL.
- OW100SSoftwave/Trt, LLC · 510(k) 2024
- DOLORCLAST Focused Shock WavesE.M.S Electro Medical Systems S.A · 510(k) 2025
- CS-Pro MEDCurative Sound Therapeutics · 510(k) 2025
- Storz Medical Duolith SD1 T-Top & Tower System with C-Actor Sepia HandpieceStorz Medical AG · 510(k) 2021
- OrthoGold 100Tissue Regeneration Technologies, LLC · 510(k) 2020
- OrthoGoldTissue Regeneration Technologies · 510(k) 2019
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.